These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 16433107)
21. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives. Horne R; Cooper V; Fisher M AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512 [TBL] [Abstract][Full Text] [Related]
22. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. Trottier B; Walmsley S; Reynes J; Piliero P; O'Hearn M; Nelson M; Montaner J; Lazzarin A; Lalezari J; Katlama C; Henry K; Cooper D; Clotet B; Arastéh K; Delfraissy JF; Stellbrink HJ; Lange J; Kuritzkes D; Eron JJ; Cohen C; Kinchelow T; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Bourdeau L; Natale C; Hughes F; Chung J; Guimaraes D; Drobnes C; Bader-Weder S; Demasi R; Smiley L; Salgo MP J Acquir Immune Defic Syndr; 2005 Dec; 40(4):413-21. PubMed ID: 16280695 [TBL] [Abstract][Full Text] [Related]
23. Localized amyloidosis at the site of enfuvirtide injection. Morilla ME; Kocher J; Harmaty M Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777 [No Abstract] [Full Text] [Related]
24. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. Moyle G J Antimicrob Chemother; 2003 Feb; 51(2):213-7. PubMed ID: 12562683 [No Abstract] [Full Text] [Related]
25. Relapse of intravenous drug use triggered by enfuvirtide, a parenteral antiretroviral medication. Avelino-Silva VI; Li HY; Novaes CT AIDS Patient Care STDS; 2012 Feb; 26(2):71-2. PubMed ID: 22148866 [TBL] [Abstract][Full Text] [Related]
26. A novel form of amyloid deposited at the site of enfuvirtide injection. Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247 [No Abstract] [Full Text] [Related]
29. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Duffalo ML; James CW Ann Pharmacother; 2003 Oct; 37(10):1448-56. PubMed ID: 14519027 [TBL] [Abstract][Full Text] [Related]
30. Development of HIV fusion inhibitors. Schneider SE; Bray BL; Mader CJ; Friedrich PE; Anderson MW; Taylor TS; Boshernitzan N; Niemi TE; Fulcher BC; Whight SR; White JM; Greene RJ; Stoltenberg LE; Lichty M J Pept Sci; 2005 Nov; 11(11):744-53. PubMed ID: 16130177 [TBL] [Abstract][Full Text] [Related]
31. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD; J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252 [TBL] [Abstract][Full Text] [Related]
32. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257 [TBL] [Abstract][Full Text] [Related]
33. [Enfuvirtide. Two injections per day for HIV]. Taéron C Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312 [No Abstract] [Full Text] [Related]
34. [Spanish recommendations for proper use of enfuvirtide]. Ribera E; Moreno S; Viciana P; Echevarría S; Flores J; Francés A; Gómez-Sirvent JL; González J; Hernández-Quero J; Lozano F; Mallolas J; Muñoz A; Ocampo A; Portilla J; Pulido F; Rivero A; Santos J; Soriano V; Antela A; Arazo P; Arribas JR; Cervantes M; Domingo P Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):131-42. PubMed ID: 17288910 [TBL] [Abstract][Full Text] [Related]
35. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Cooper DA; Lange JM Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553 [TBL] [Abstract][Full Text] [Related]
36. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV. Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955 [No Abstract] [Full Text] [Related]
37. Enfuvirtide access, administration, and patient education. Celano SA Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102 [No Abstract] [Full Text] [Related]
38. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M; N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645 [TBL] [Abstract][Full Text] [Related]
39. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients. Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088 [TBL] [Abstract][Full Text] [Related]
40. In vitro characterization of a sustained-release formulation for enfuvirtide. Rothstein SN; Huber KD; Sluis-Cremer N; Little SR Antimicrob Agents Chemother; 2014; 58(3):1797-9. PubMed ID: 24366751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]